CSTLCSTLHealthcare · Diagnostics & Research

CSTL Stock Forecast: Castle Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Nov 2026
$34
−1.42% on the day

The 9 Wall Street analysts covering Castle Biosciences, Inc. hold a median 12-month price target of $46 — +35.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 11 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.1B
Ticker Nerd rank
94/ 100
Median analyst target
$46
Analysts covering
9
Revenue$103.5M+20.1% y/y
Operating income−$3.1M
Net income−$2.1M
Free cash flow$6.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−1.4%
YTD
−12.8%
1Y
−3.0%
From 52W high
−21.2%
From 52W low
+86.9%
$18
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CSTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Castle Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
94/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Momentum
86
Volatility
78
Value
73
Accruals
73
Quality
71
Growth
63
Issuance
48
Size
43

Revisions (97): Analysts have, on balance, been raising their forecasts.

Issuance (48): The company has been issuing shares or taking on financing, diluting existing holders.

Size (43): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CSTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CSTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26CSTLHigh $60Median $46Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $40Median $46High $60

The green dot is the last close — the median target sits +35.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026BairdMaintainsOutperform$39 → $41
9 Nov 2026BTIGMaintainsBuy$44 → $52
6 Nov 2026KeybancMaintainsOverweight$35 → $40
3 Aug 2026BTIGMaintainsBuy$40 → $44
3 Aug 2026BTIGMaintainsBuy—
25 June 2026Roth CapitalInitiatesBuy$40
25 June 2026Roth CapitalInitiatesBuy—
13 May 2026BTIGMaintainsBuy—
7 May 2026BairdMaintainsOutperform—
20 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026BairdMaintainsOutperform—
26 Jan 2026GuggenheimMaintainsBuy—
12 Jan 2026Lake StreetMaintainsBuy—
5 Jan 2026GuggenheimMaintainsBuy—
22 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025BTIGMaintainsBuy—
5 Nov 2025BTIGMaintainsBuy—
4 Nov 2025BairdMaintainsOutperform—
9 Sept 2025Canaccord GenuityMaintainsBuy—
21 May 2025ScotiabankMaintainsSector Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CSTL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CSTL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Nov 2026, Castle Biosciences, Inc. returned −3.0% against +12.4% for the S&P 500, dividends included.

CSTL vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CSTLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CSTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Castle Biosciences, Inc. (CSTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.5×

Cheaper than 25% of US stocks

Price / sales
2.8×

Cheaper than 41% of US stocks

Price / book
2.2×

Cheaper than 39% of US stocks

EV / EBITDA
−67.9×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
23.9%

Higher than 73% of US stocks

Earnings growth (YoY)
20.1%

Higher than 60% of US stocks

Gross margin
77.1%

Higher than 89% of US stocks

Operating margin
−2.7%

Higher than 29% of US stocks

Net margin
−6.1%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−4.9%

Higher than 39% of US stocks

Return on assets
−3.1%

Higher than 35% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Castle Biosciences, Inc. (CSTL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Castle Biosciences, Inc. has a market value of $1.1B and an enterprise value of $819.7M.

  • Revenue in the twelve months to 30 June 2026: $357.3M. The latest quarter grew 23.9% year on year.

  • Net income over the same four quarters: −$19.4M, a −5.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.66.

  • Free cash flow in the twelve months to 30 June 2026: −$489K.

  • Shares outstanding: 30.5M.

  • Trailing P/E: 30.5×; forward P/E: −43.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Castle Biosciences, Inc. employs 1,048 people — $341K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Nov 2026

Data provided by Twelve Data

Peers

CSTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CSTLCastle Biosciences, Inc.$1.1B94
FRNMFreenome, Inc.$1.3B30
OPKOPKO Health, Inc.$1.3B67
FLGTFulgent Genetics, Inc.$729.9M72
WGSGeneDx Holdings Corp.$1.6B46
PSNLPersonalis, Inc.$1.7B51
VCYTVeracyte, Inc.$2.0B76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Castle Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CSTL news & analysis

Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture

PRNewsWire · 12 Nov 2026positive

Castle Biosciences announced 2026 Top Workplaces recognition, including regional awards in Houston, Arizona and Pittsburgh, a national healthcare industry award, and eight Culture Excellence awards. The company said the awards, based on employee feedback, bring its total honors to 13.

Why it matters — The recognition provides CSTL watchers with an update on employee feedback and the company’s workplace culture.

Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference

PRNewsWire · 11 Nov 2026neutral

Castle Biosciences announced that its executive management is scheduled to present a company overview at the Piper Sandler 38th Annual Healthcare Conference on Dec. 2, 2026, at 8:10 a.m. Eastern time.

Why it matters — CSTL watchers may note the scheduled conference presentation as an opportunity for management to discuss the company.

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

PRNewsWire · 11 Nov 2026positive

Castle Biosciences announced it will present DecisionDx-Melanoma analyses at SDPA and Dermato-Onco2026. The analyses report identifying higher-risk patients among those with thin melanoma and providing individualized five-year recurrence-risk estimates for stage I–III melanoma.

Why it matters — The presentations highlight data on how DecisionDx-Melanoma may refine risk assessment beyond AJCC staging and inform individualized follow-up and surveillance.

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade

Zacks Investment Research · 10 Nov 2026positive

Zacks Investment Research reports that analysts’ consensus price target implies 37% upside potential for Castle Biosciences. The excerpt cautions that this metric is not very effective, while noting that upward earnings estimate revisions may indicate near-term upside.

Why it matters — CSTL watchers may note the consensus target and earnings estimate trend, alongside the caveat about the target metric’s limited effectiveness.

What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call

MarketBeat · 6 Nov 2026positive

Castle Biosciences reported 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test, and raised its full-year revenue outlook.

Why it matters — The update highlights growth in TissueCypher demand and a higher revenue outlook for CSTL.

FAQ

Frequently asked questions about CSTL stock

What is the CSTL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Castle Biosciences, Inc. have a median 12-month price target of $46, with estimates ranging from $40 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CSTL stock a buy right now?

Of the 9 analysts covering Castle Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Castle Biosciences, Inc. 94 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CSTL?

As at 11 Nov 2026, Castle Biosciences, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will CSTL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +35.6% from the last close, and Ticker Nerd's factor model ranks Castle Biosciences, Inc. 94 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CSTL stock forecast for 2030?

No analyst covering Castle Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $60 over the next 12 months.

How has CSTL stock performed over the past year?

Castle Biosciences, Inc. returned -3.0% over the 12 months to 11 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Castle Biosciences, Inc. do?

Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making.

What is the latest news on CSTL?

The most recent item we track (PRNewsWire, 12 Nov 2026): "Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture". Castle Biosciences announced 2026 Top Workplaces recognition, including regional awards in Houston, Arizona and Pittsburgh, a national healthcare industry award, and eight Culture Excellence awards. The company said the awards, based on employee feedback, bring its total honors to 13.

Company

About Castle Biosciences, Inc.

Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.

CEO Mr. Derek J. Maetzold · 1,048 employees · United States · https://castlebiosciences.com